Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes

European Journal of Haematology

Volumn 95, Issue 3, 2015, Pages 181-189

  Schemenau, Jennifer ^a   Baldus, Stephan ^a   Anlauf, Martin ^a   Reinecke, Petra ^a   Braunstein, Stefan ^a   Blum, Sabine ^b   Nachtkamp, Kathrin ^a   Neukirchen, Judith ^a   Strup, Corinna ^a   Aul, Carlo ^c   Haas, Rainer ^a   Gattermann, Norbert ^a   Germing, Ulrich ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c ST JOHANNES HOSPITAL   (Germany)

Author keywords

Bone marrow cellularity; Cytogenetics; Myelodysplastic syndromes; Prognosis

Indexed keywords

ADOLESCENT; ADULT; AGED; CONTROLLED STUDY; CYTOLOGY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FIBROSIS; HEMATOLOGICAL PARAMETERS; HIGH RISK POPULATION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL; SURVIVAL RATE; BLOOD; BLOOD EXAMINATION; BONE MARROW; GENETICS; LEUKEMIA, MYELOID, ACUTE; META ANALYSIS; MORTALITY; MYELODYSPLASTIC SYNDROMES; PATHOLOGY;

BONE MARROW; DISEASE PROGRESSION; FEMALE; HEMATOLOGIC TESTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84938999239     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12512     Document Type: Review

References (21)

1. Brunning RD, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, et al., eds: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC press; 2008: 87-104.
2. Brunning RD, Germing U. Myelodysplastic syndromes. In: Orazi A, Weiss LM, Foucar K, Knowles DM. Neoplastic Hematopathology, 3rd edn. Philadelphia: Lippinscott Williams & Wilkins, 2014: 1076-1107.
3. Stadler M, Germing U, Kliche KO, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004;18:460-5.
4. Jonásova A, Neuwirtová R, Cermák J, Vozobulová V, Mociková K, Sisková M, Hochová I. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998;100:304-9.
5. Sloand EM, Olnes MJ, Shenoy A, et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol 2010;28:5166-73.
6. Neukirchen J, Platzbecker U, Sockel K, Tsamaloukas A, Haas R, Germing U. Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow. Ann Hematol 2014;93:65.
7. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003;102:3025-7.
8. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992;6:52-9.
9. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
10. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-65.
11. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-10.
12. Tong WG, Quintás-Cardama A, Kadia T, et al. Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. Cancer 2012;118:4462-70.
13. Tuzuner N, Cox C, Rowe JM, Bennett JM. Bone marrow cellularity in myeloid stem cell disorders: impact of age correction. Leuk Res 1994;18:559-64.
14. Hartsock RJ, Smith EB, Petty CS. Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior ilias crest. A study made from 177 cases of sudden death examined by necropsy. Am J Clin Pathol 1965;43:326-31.
15. Buesche G, Teoman H, Wilczak W, et al. Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 2008;22:313-22. Epub 2007 Nov 22.
16. Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 2009;27:754-62.
17. Maschek H, Kaloutsi V, Rodriguez-Kaiser M, Werner M, Choritz H, Mainzer K, Dietzfelbinger M, Georgii A. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. Ann Hematol 1993;66:117-22.
18. Tuzuner N, Cox C, Rowe JM, Watrous D, Bennett JM. Hypocellular myelodysplastic syndromes (MDS): new proposals. Br J Hematol 1995;91:612-7.
19. Corrêa de Souza D, de Souza Fernandez C, Camargo A, Apa AG, Sobral da Costa E, Bouzas LF, Abdelhay E, de Souza Fernandez T. Cytogenetic as an important tool for diagnosis and prognosis for patients with hypocellular primary myelodysplastic syndrome. Biomed Res Int. 2014;2014:542395.
20. Huang TC, Ko BS, Tang JL, et al. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies. Leukemia 2008;22:544-50.
21. Itzykson R, Smith A, de Witte T, et al. Prognostic relevance of the kinetics of worsening of cytopenias in lower-risk MDS: a substudy from the European Leukemianet Low Risk MDS (EUMDS) Registry. Blood 2012;120:700.